<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220725</url>
  </required_header>
  <id_info>
    <org_study_id>14-504</org_study_id>
    <nct_id>NCT02220725</nct_id>
  </id_info>
  <brief_title>A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Portola Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Portola Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the
      anticoagulation effect of Rivaroxaban.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of Rivaroxaban anticoagulation effect as measured by anti-factor Xa activity</measure>
    <time_frame>43 Days</time_frame>
    <description>To compare reversal of Rivaroxaban anticoagulation between Andexanet Alpha and placebo measured by anti-fXa activity for bolus followed by continuous infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unbound rivaroxaban plasma levels</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin Generation</measure>
    <time_frame>43 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Andexanet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Andexanet (antidote)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Andexanet</intervention_name>
    <arm_group_label>Andexanet</arm_group_label>
    <other_name>Andexanet alpha</other_name>
    <other_name>PRT4445</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reasonably healthy men and women aged 50 to 75

        Exclusion Criteria:

          -  History of abnormal bleeding, active bleeding or risk factors for bleeding

          -  History of thrombosis or risk factors for thrombosis

          -  History of adult asthma or use of inhaled medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vandana Mathur, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Portola Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2014</study_first_posted>
  <disposition_first_submitted>September 19, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>September 19, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 27, 2017</disposition_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Andexanet alpha</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Antidote</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Anti-fXa inhibitor</keyword>
  <keyword>PRT4445</keyword>
  <keyword>Xarelto</keyword>
  <keyword>Reversal agent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

